A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors

Memorial Sloan Kettering Cancer Center (MSK)

Status and phase

Enrolling

Early Phase 1

Conditions

Brain Metastases, Adult

Brain Metastases

High-grade Glioma

Treatments

Diagnostic Test: 68Ga-PSMA-11 PET Scans

Study type

Interventional

Funder types

Other

Identifiers

NCT06209567

23-382

Details and patient eligibility

About

The purpose of this study is to find out whether 68Ga-PSMA-11 PET/CT is effective in assessing tumor uptake (tumor activity seen in cancerous tissue) in participants with high-grade glioma/HGG or brain metastases.

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Ability to understand and the willingness to sign (or their legally acceptable representative (LAR) must sign) a written informed consent document
Adults ≥ 18 years old
Suspicion for or histologically or cytologically confirmed and previously treated HGG or brain metastases from a primary extracranial malignancy
Lesion size ≥ 1 cm (for the lesion to be biopsied)
ECOG performance status ≤ 2 (Karnofsky ≥ 60%)
Planned to undergo biopsy/resection of brain lesion

Exclusion criteria

Inability to undergo a PET scan (e.g., claustrophobia or noncompatible implant in case PET/MR is performed)
Pregnant or nursing female. All women of childbearing potential must have a documented negative serum or urine pregnancy test <1 week before study.
Uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiacarrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Patients with severe allergy to both iodinated and gadolinium contrast.